TILMICABS INJECTION

Država: Australija

Jezik: engleski

Izvor: APVMA (Australian Pesticides and Veterinary Medicines Authority)

Aktivni sastojci:

TILMICOSIN PHOSPHATE

Dostupno od:

ABBEY LABORATORIES PTY LTD

Farmaceutski oblik:

PARENTERAL LIQUID/SOLUTION/SUSPENSION

Sastav:

TILMICOSIN PHOSPHATE ANTIBIOTIC Active 300.0 mg/ml

Jedinice u paketu:

100 mL; 250 mL

Razred:

VM - Veterinary Medicine

Područje terapije:

ANTIBIOTIC & RELATED

Proizvod sažetak:

Poison schedule: 4; Withholding period: MEAT: DO NOT USE less than 28 days befor e slaughter for human consumption. MILK : DO NOT USE in lactating cows where mil k may be used or processed for human co nsumption. Any variation by the prescri bing veterinarian to the approved dose, frequency, duration, route, disease or target species may require extending the approved withholding period. DO NOT US E less than 42 days before slaughter for export. Before using this product, conf irm the current ESI from Abbey Animal He alth Pty Ltd on 02 8088 0720 or the APVM A website (www.apvma.gov.au/residues/ESI .html); Host/pest details: CATTLE: [BOVINE RESPIRATORY DISEASE, MANNHEIMIA HAEMOLYTICA, PASTEURELLA MULTOCIDA]

Status autorizacije:

Registered

Datum autorizacije:

2023-07-01

Uputa o lijeku

TILMICABS INJECTION
86875/116870
Product Name:
APVMA Approval No:
Label Name:
TILMICABS INJECTION
Signal Headings:
PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
Constituent
Statements:
300 mg/mL Tilmicosin (as Tilmicosin phosphate)
Claims:
For use in lot-fed cattle for the treatment of Bovine Respiratory
Disease (BRD) associated
with Mannheimia (Pasteurella) haemolytica, Pasteurella multocida and
other organisms
susceptible to Tilmicosin.
Net Contents:
100 mL, 250 mL
Directions for Use:
Restraints:
DO NOT USE in lactating cows where milk may be used or processed for
human
consumption.
Contraindications:
This product is contraindicated for use in pigs, goats and non-human
primates. Injection
has been shown to be fatal in pigs, non-human primates, goats, sheep
(intravenous
injection) and lambs less than 15kg bodyweight. Tilmicosin may be
fatal in horses.
Precautions:
Inject subcutaneously only in cattle. This product must not be
administered intravenously or
intramuscularly. Intravenous injection in cattle has been fatal.
Pneumatic or hydraulically operated syringes should not be used with
this product.
The safety of Tilmicosin has not been established in pregnant cattle.
Side Effects: RLP APPROVED
Dosage and
Administration:
Use contents of vial within 90 days of initial broaching and discard
any unused portion.
Administer a single subcutaneous injection of 10 mg Tilmicosin per kg
bodyweight (1 mL
per 30 kg) using a standard disposable syringe or multi-filling
syringe.
With a single hand on the syringe, insert the needle subcutaneously,
at a top-down angle,
whilst avoiding penetration underlying muscle.
Do not inject more than 25 mL per injection site. Subcutaneous
injection must be made
high into the neck. If no improvement is noted within 48 hours, the
diagnosis should be re-
evaluated. Single dose only.
NOTE: Swelling at the subcutaneous site of injection may be observed
but is transient and
usually mild.
General Directions:
Properly restrain animals prior to administration.